RxDoctor Payments Data

Marjorie Christopher

Family · Macon, GANPI 1790261535

Payments from drug & device makers

$4,699in general payments, 2019–2025

Across 265 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$636
  • Lilly USA, LLC$612
  • Novo Nordisk$596
  • AstraZeneca$421
  • Pfizer$371
  • AbbVie$325
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,687100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,699 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$90,978
Medicare patients
458
Services billed
1,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$138,250
EliquisApixaban47$47,316
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$26,710
FarxigaDapagliflozin Propanediol24$25,978
LinzessLinaclotide23$22,055
JardianceEmpagliflozin16$17,113
MounjaroTirzepatide15$16,024
MyrbetriqMirabegron11$11,019
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$4,457
SynthroidLevothyroxine Sodium45$4,164
Albuterol Sulfate HfaAlbuterol Sulfate157$3,047
Levothyroxine Sodium197$2,230
Gabapentin95$1,877
Fluticasone Propionate76$1,682
Venlafaxine Hcl ErVenlafaxine Hcl19$1,556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$596$138,25092 claims
PfizerEliquis$371$47,31647 claims
GSKTrelegy Ellipta$207$26,71027 claims
AbbVieLinzess, Synthroid$325$26,22068 claims
AstraZenecaFarxiga$421$25,97824 claims
Boehringer IngelheimJardiance$148$17,11316 claims
Lilly USA, LLCMounjaro$612$16,02415 claims
Astellas Pharma US IncMyrbetriq$24$11,01911 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$64$2,230197 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →